GLP-1 adherence data is surprisingly bad: 44% of users aren't following protocol. 28% straight up skip doses, rest are underdosing, delaying refills, or just quitting. This matters because these drugs (Ozempic, Wegovy, etc.) need consistent blood levels to work - they're incretin mimetics that regulate insulin and slow gastric emptying. Skip doses and you lose the metabolic benefits, plus risk rebound weight gain. The bigger question: is this a UX problem (weekly injections are annoying), cost issue (insurance gaps), or side effect management (nausea makes people bail)? Either way, the effectiveness gap between clinical trials and real-world use is massive.